100 related articles for article (PubMed ID: 11221516)
21. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
Martinez SR; Hoon DS
J Cell Biochem; 2005 Oct; 96(3):473-83. PubMed ID: 16088931
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
24. Markers of high-risk cutaneous melanoma: is there a winning combination for individualized prognosis?
Carlson JA; Ross J; Murphy M
J Cutan Pathol; 2005 Nov; 32(10):700-3. PubMed ID: 16293184
[No Abstract] [Full Text] [Related]
25. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
26. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
27. Melanoma simulating atypical fibroxanthoma.
Sangüeza M; Zelger B
Am J Dermatopathol; 2007 Dec; 29(6):551-4. PubMed ID: 18032950
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
Winnepenninckx V; van den Oord JJ
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
[TBL] [Abstract][Full Text] [Related]
29. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
32. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
34. Pathology of melanocytic lesions: new, controversial, and clinically important issues.
Scolyer RA; Thompson JF; Stretch JR; Sharma R; McCarthy SW
J Surg Oncol; 2004 Jul; 86(4):200-11. PubMed ID: 15221927
[TBL] [Abstract][Full Text] [Related]
35. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.
Alonso SR; Tracey L; Ortiz P; Pérez-Gómez B; Palacios J; Pollán M; Linares J; Serrano S; Sáez-Castillo AI; Sánchez L; Pajares R; Sánchez-Aguilera A; Artiga MJ; Piris MA; Rodríguez-Peralto JL
Cancer Res; 2007 Apr; 67(7):3450-60. PubMed ID: 17409456
[TBL] [Abstract][Full Text] [Related]
36. Osteopontin as a molecular prognostic marker for melanoma.
Rangel J; Nosrati M; Torabian S; Shaikh L; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Cancer; 2008 Jan; 112(1):144-50. PubMed ID: 18023025
[TBL] [Abstract][Full Text] [Related]
37. Molecular staging for patients with malignant melanoma.
Shivers S; Jakub J; Pendas S; Reintgen D
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1665-74. PubMed ID: 18020932
[TBL] [Abstract][Full Text] [Related]
38. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.
Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U
J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
[TBL] [Abstract][Full Text] [Related]
40. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
